First & only once-daily triple therapy in a single inhaler for adult patients with ASTHMA

For patients aged 18+ who continue to experience symptoms on an ICS/LABA

TRELEGY is available in 2 strengths for adult patients with ASTHMA

TRELEGY is NOT indicated for relief of acute bronchospasm

For Asthma Inhalers
For Asthma Inhalers

Significant lung function improvement with TRELEGY for adult patients with ASTHMA

In a 24- to 52-week study of TRELEGY vs BREO, an ICS/LABA

Primary endpoint: change from baseline in trough FEV1 at Week 24


TRELEGY 100/62.5/25 mcg

Asthma Graph 1

TRELEGY 200/62.5/25 mcg

Asthma Graph 2
  • CAPTAIN study description1

    Design: A 24- to 52-week, randomized, double-blind, active-controlled, parallel-group, multicenter study that evaluated the safety and efficacy of TRELEGY 100/62.5/25 mcg and TRELEGY 200/62.5/25 mcg compared with BREO 100/25 mcg and BREO 200/25 mcg, respectively (each administered once daily in the morning).

    Patients: Patients ≥18 years were eligible if they had inadequately controlled asthma (ACQ-6 score ≥1.5) while receiving daily ICS/LABA (ICS dose >250 mcg fluticasone propionate or equivalent) for ≥12 weeks pre-study. After a 5-week run-in and stabilization period, 2436 patients were randomized to treatment (mean age 53 years, baseline mean percent predicted FEV1 68%).


What are TRELEGY dosing considerations for ASTHMA?

See details


You can request TRELEGY savings offers for eligible patients.

Find out how


See local coverage for TRELEGY vs other therapies. 

Compare now

Get samples of TRELEGY in both strengths for adult patients with ASTHMA.

Learn more